Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

被引：0
|
作者：
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Gustave Roussy Canc Campus, Villejuif, France
[5] Univ Paris Sud, Villejuif, France
[6] Duke Univ, Sch Med, Cary, NC USA
[7] Inst Curie, Paris, France
[8] Royal Marsden Hosp, London, England
[9] Studienpraxis Urol, Nurtingen, Germany
[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[11] Univ Western Ontario, Brampton, ON, Canada
[12] Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[14] UCL, Inst Canc, London, England
[15] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[16] Macquarie Univ Hosp, Sydney, NSW, Australia
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：2
相关论文
共 50 条
  • [31] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
    Hoimes, Christopher J.
    Graff, Julie N.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Gerritsen, Winald R.
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
    Yu, Evan Y.
    Joshua, Anthony M.
    Kramer, Gero
    Shore, Neal D.
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS249 - TPS249
  • [33] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
    Fong, Peter C. C.
    Kwiatkowski, Mariusz
    Mosca, Alessandra
    Valderrama, Begona Perez
    Huang, Yi-Hsiu
    Zedan, Ahmed H.
    Kuc, Kamil
    Wiechno, Pawel
    Laguerre, Brigitte
    Gonzalez-Billalabeitia, Enrique
    Osipov, Mikhail
    Dede, Didem Sener
    Goh, Jeffrey
    Daugaard, Gedske
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    Arija, Jose Angel Arranz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
  • [34] Biomarker analysis of men with enzalutamide (enza)resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) plus enza in KEYNOTE-199
    Graff, J. N.
    Tagawa, S.
    Hoimes, C.
    Gerritsen, W.
    Vaishampayan, U. N.
    Elliott, T.
    Hwang, C.
    Ten Tije, A. J.
    Omlin, A. G.
    McDermott, R. S.
    De Wit, R.
    Qiu, P.
    Poehlein, C.
    Kim, J.
    Suttner, L.
    Cristescu, R.
    Marton, M. J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S383 - S383
  • [35] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [36] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Linch, M.
    Ferrario, C.
    Stoeckle, M.
    Laguerre, B.
    Arija, J. A. Arranz
    Todenhofer, T.
    Fong, P. C.
    Rodriguez, J. M. Piulats
    Berry, W.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
  • [37] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
    Yu, Evan Y.
    Joshua, Anthony M.
    Shore, Neal D.
    Kramer, Gero
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
  • [38] Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
    Vaishampayan, U. N.
    Elliott, T.
    Omlin, A. G.
    Graff, J. N.
    Hoimes, C. J.
    Tagawa, S. T.
    Hwang, C.
    Kilari, D.
    Ten Tije, A. J.
    McDermott, R. S.
    Gerritsen, W. R.
    Wu, H.
    Kim, J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1330 - S1330
  • [39] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [40] Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5
    Graff, Julie Nicole
    Antonarakis, Emmanuel S.
    Hoimes, Christopher J.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius Gabriel
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Anthony
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345